ReviewInternational journal of nanomedicine2025
Wound Healing: Harnessing Extracellular Vesicles Derived from Adipose-Derived Stem Cells.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.Frontiers in cell and developmental biology · 2026Review
- Applications of Nanomaterials in Chronic Wound Healing and Scar Prevention.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wounds present a significant clinical challenge, placing a heavy burden on patients and highlighting the need for more effective treatments. Among emerging strategies, adipose-derived stem cells (ADSCs) and their extracellular vesicles (ADSC-EVs) show great promise due to their potent wound-healing capabilities. Clinical evidence indicates that ADSC transplantation effectively promotes healing across diverse chronic wound types, improving healing quality while reducing pathological scarring. As key paracrine mediators of ADSCs, ADSC-EVs have garnered considerable interest for their advantages in therapeutic development and reparative functions. ADSC-EVs precisely modulate critical cells within the wound microenvironment, including keratinocytes, macrophages, endothelial cells, and fibroblasts. This modulation promotes re-epithelialization, resolves inflammation, stimulates angiogenesis, and modulates extracellular matrix remodeling. These regulatory effects are attributed to the rich cargo of bioactive molecules carried by ADSC-EVs, including proteins and non-coding RNAs. Notably, preconditioning strategies and functional delivery materials can further enhance the modulatory effects of ADSC-EVs by enriching them with specific therapeutic molecules and enabling controlled release. Furthermore, ADSC-EVs serve as efficient drug delivery vehicles for exogenous therapeutics, enabling synergistic effects. In summary, both ADSCs and ADSC-EVs demonstrate considerable clinical potential for chronic wound management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.